(SLS) Sellas Life Sciences - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.669m USD | Total Return: 342.1% in 12m

Immunotherapies, Cancer Vaccines, CDK9 Inhibitors, Peptide Therapeutics
Total Rating 43
Safety 64
Buy Signal 0.33
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.67B
Avg Turnover: 31.4M
Risk 3d forecast
Volatility165%
VaR 5th Pctl25.2%
VaR vs Median-7.67%
Reward TTM
Sharpe Ratio2.00
Rel. Str. IBD99.1
Rel. Str. Peer Group95.3
Character TTM
Beta0.441
Beta Downside-0.935
Hurst Exponent0.610
Drawdowns 3y
Max DD72.35%
CAGR/Max DD0.96
CAGR/Mean DD2.62
EPS (Earnings per Share) EPS (Earnings per Share) of SLS over the last years for every Quarter: "2021-03": -0.16, "2021-06": -0.3, "2021-09": -0.45, "2021-12": -0.42, "2022-03": -1.05, "2022-06": -0.41, "2022-09": -0.34, "2022-12": -0.43, "2023-03": -0.47, "2023-06": -0.31, "2023-09": -0.33, "2023-12": -0.25, "2024-03": -0.21, "2024-06": -0.13, "2024-09": -0.1, "2024-12": -0.08, "2025-03": -0.07, "2025-06": -0.07, "2025-09": -0.06, "2025-12": -0.05, "2026-03": -0.0487,
Last SUE: 0.41
Qual. Beats: 0
Revenue Revenue of SLS over the last years for every Quarter: 2021-03: 5.7, 2021-06: 1.9, 2021-09: 0, 2021-12: -7.6, 2022-03: 1, 2022-06: 0, 2022-09: 0, 2022-12: -1, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: 0,
Last SUE: 0.00
Qual. Beats: 0

Warnings

Share dilution 96.5% YoY

Interest Coverage Ratio -2.0 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

Leader, Confidence

Description: SLS Sellas Life Sciences

SELLAS Life Sciences Group (SLS) is a late-stage clinical biopharmaceutical firm headquartered in New York, specializing in cancer therapeutics. The company’s primary pipeline consists of galinpepimut-S (GPS), a WT1-targeting peptide immunotherapy, and SLS009, a selective CDK9 inhibitor. These assets are being evaluated for both hematologic malignancies and solid tumors through strategic collaborations with Merck & Co., GenFleet Therapeutics, and Memorial Sloan Kettering Cancer Center.

The biotechnology sector often utilizes peptide immunotherapies to prime the immune system to recognize and attack specific tumor antigens, a method designed to minimize damage to healthy tissue. Developing late-stage oncology assets requires significant capital for Phase 3 trials and regulatory filing processes. Investors may find additional context on these clinical milestones by reviewing ValueRay.

Headlines to Watch Out For
  • Phase 3 REGAL trial data for GPS in AML remains primary valuation catalyst
  • Clinical trial progress of CDK9 inhibitor SLS009 drives investor sentiment and pipeline expansion
  • Strategic partnerships and licensing agreements provide essential non-dilutive funding and validation
  • Cash runway and frequent equity offerings impact share price stability and liquidity
  • Regulatory milestones and potential FDA approvals dictate long-term commercial viability and revenue
Piotroski VR-10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.25 > 0.02 and ΔFCF/TA 71.77 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.25 > 3% & CFO -28.2m > Net Income -29.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 17.22 > 1.5 & < 3
Outstanding Shares: last quarter (172.5m) vs 12m ago 96.54% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -1.99 > 6 (EBITDA TTM -31.5m / Interest Expense TTM 15.8m)
Altman Z'' -15.00
A: 0.92 (Total Current Assets 111.2m - Total Current Liabilities 6.46m) / Total Assets 114.2m
B: -2.48 (Retained Earnings -283.4m / Total Assets 114.2m)
C: -0.42 (EBIT TTM -31.5m / Avg Total Assets 74.6m)
D: -41.89 (Book Value of Equity -283.4m / Total Liabilities 6.76m)
Altman-Z'' = -48.89 = D
What is the price of SLS shares?

As of May 24, 2026, the stock is trading at USD 7.56 with a total of 24,765,536 shares traded.
Over the past week, the price has changed by +9.89%, over one month by +62.76%, over three months by +72.89% and over the past year by +342.05%.

Is SLS a buy, sell or hold?

Sellas Life Sciences has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SLS.

  • StrongBuy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the SLS price?
Analysts Target Price 10 32.3%
Sellas Life Sciences (SLS) - Fundamental Data Overview as of 22 May 2026
P/S = 26.8951
P/B = 13.1628
Revenue TTM = 0.0 USD
EBIT TTM = -31.5m USD
EBITDA TTM = -31.5m USD
Long Term Debt = 309k USD (estimated: total debt 871k - short term 562k)
Short Term Debt = 562k USD (from shortTermDebt, last quarter)
Debt = 871k USD (from shortLongTermDebtTotal, last quarter) (leases 871k already included)
Net Debt = -106.3m USD (calculated: Debt 871k - CCE 107.2m)
Enterprise Value = 1.56b USD (1.67b + Debt 871k - CCE 107.2m)
Interest Coverage Ratio = -1.99 (Ebit TTM -31.5m / Interest Expense TTM 15.8m)
EV/FCF = -55.47x (Enterprise Value 1.56b / FCF TTM -28.2m)
FCF Yield = -1.80% (FCF TTM -28.2m / Enterprise Value 1.56b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 13.68 (Enterprise Value 1.56b / Total Assets 114.2m)
 Interest Expense / Debt = 1.81k% (Interest Expense 15.8m / Debt 871k)
 Taxrate = 21.0% (US default 21%)
NOPAT = -24.9m (EBIT -31.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.22 (Total Current Assets 111.2m / Total Current Liabilities 6.46m)
Debt / Equity = 0.01 (Debt 871k / totalStockholderEquity, last quarter 107.4m)
 Debt / EBITDA = 3.38 (negative EBITDA) (Net Debt -106.3m / EBITDA -31.5m)
 Debt / FCF = 3.78 (negative FCF - burning cash) (Net Debt -106.3m / FCF TTM -28.2m)
 Total Stockholder Equity = 62.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.50% (Net Income -29.5m / Total Assets 114.2m)
RoE = -8.52% (Net Income TTM -29.5m / Total Stockholder Equity 345.9m)
RoCE = -9.09% (EBIT -31.5m / Capital Employed (Equity 345.9m + L.T.Debt 309k))
 RoIC = -25.07% (negative operating profit) (NOPAT -24.9m / Invested Capital 99.2m)
 WACC = 7.53% (E(1.67b)/V(1.67b) * Re(7.53%) + (debt cost/tax rate unavailable))
Discount Rate = 7.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 115.0%
 [DCF] Fair Price = unknown (Cash Flow -28.2m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.41 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.05 | Chg30d=+25.04% | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.06 | Chg30d=+24.97% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.21 | Chg30d=+25.87% | Revisions=+33% | GrowthEPS=+16.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.15 | Chg30d=+16.67% | Revisions=+14% | GrowthEPS=+28.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +33%